Moperone (Luvatren, since discontinued) is a typical antipsychotic of the butyrophenone class[2] which is marketed in Japan for the treatment of schizophrenia.

It is an antagonist for the D2 (Ki 0.7–1.9 nM), D3 (Ki 0.1–1 nM), and 5-HT2A (Ki 52 nM) receptors.

It also has a high binding affinity for the sigma receptors.

[3][4] This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.